Design Therapeutics (NASDAQ:DSGN – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02. On average, analysts expect Design Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.63) EPS for the next fiscal year.
Design Therapeutics Price Performance
Shares of DSGN stock opened at $10.15 on Tuesday. The company’s fifty day simple moving average is $12.56 and its two-hundred day simple moving average is $12.13. Design Therapeutics has a 1 year low of $6.16 and a 1 year high of $17.25. The stock has a market capitalization of $635.21 million, a price-to-earnings ratio of -8.60 and a beta of 1.68.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on DSGN shares. Wells Fargo & Company started coverage on Design Therapeutics in a report on Friday, October 2nd. They set an “overweight” rating and a $26.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.86.
Read Our Latest Report on Design Therapeutics
About Design Therapeutics
Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.
The company’s research has focused on disorders affecting the nervous system, muscles and eyes.
Read More
- Five stocks we like better than Design Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
